Search results for "SART"

showing 10 items of 212 documents

Ethylene-vinyl alcohol copolymer (Onyx®) transarterial embolization for post-traumatic high-flow priapism

2016

International audience; We report a case of high-flow priapism treated successfully with superselective embolization of the cavernous artery. A 16-year-old male developed post-traumatic priapism subsequent to a fall causing blunt perineal trauma. He presented to our hospital four days after trauma. Immediately after the injury, he suffered painless sustained incomplete erection. High-flow priapism was diagnosed on the basis of color doppler ultrasonography findings. Computed tomography scan showed a high-flow arterio-venous fistula with feeders from branches of the right internal iliac artery. Selective arteriography of the right internal pudendal artery demonstrated an arterio-cavernous fi…

medicine.medical_specialty[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingFistulaPriapism030232 urology & nephrologyCase ReportComputed tomography[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBlunttransarterial embolizationEthylene vinyl alcohol copolymerTransarterial embolizationmedicineethylene-vinyl alcohol copolymerRadiology Nuclear Medicine and imaging[ SDV.IB ] Life Sciences [q-bio]/BioengineeringHigh-flow priapism[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/Imagingmedicine.diagnostic_testbusiness.industrycomputed tomographyColor dopplerHigh flow priapismmedicine.disease3. Good healthSurgery[SDV.IB]Life Sciences [q-bio]/BioengineeringRadiologybusinessQuantitative Imaging in Medicine and Surgery
researchProduct

Meta-analysis of blood pressure (BP) reductions with olmesartan medoxomil (OM) compared with active control (AC) in patients (pts) with hypertension …

2015

Meta-analysis of blood pressure (BP) reductions with olmesartan medoxomil (OM) compared with active control (AC) in patients (pts) with hypertension (HTN) Josep Redon,y, 6 Prakash Deedwania, Kazuomi Kario, Jiguang Wang, Joris Versteden, Paul-Egbert Reimitz. Daiichi Sankyo Europe GmbH, Munich, Germany; Daiichi Sankyo Europe GmbH, Munich, Germany; Jichi University School of Medicine, Japan; Shanghai Institute of Hypertension, Shanghai, China; University of California San Francisco, San Francisco, CA, United States; University of Valencia, Madrid, Spain

medicine.medical_specialtybusiness.industryActive controlEndocrinologyBlood pressureInternal medicineMeta-analysisInternal MedicinemedicineIn patientCardiology and Cardiovascular MedicinebusinessOlmesartanmedicine.drugJournal of the American Society of Hypertension
researchProduct

Vascular Dysfunction in Nitroglycerininduced Nitrate Tolerance is Improved by Telmisartan Therapy — Suppression of the RAAS and PKC Pathway

2010

medicine.medical_specialtybusiness.industryPharmacologyBiochemistrychemistry.chemical_compoundEndocrinologyNitratechemistryPhysiology (medical)Internal medicinemedicineTelmisartanbusinessProtein kinase Cmedicine.drugFree Radical Biology and Medicine
researchProduct

Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide

2021

Abstract Treatment of hepatocellular carcinoma (HCC) depends on the stage of disease. In the Western Hemisphere, the Barcelona Clinic Liver Cancer classification (BCLC) is the preferred staging system. Approximately one-third of patients initially present with intermediate-stage disease. For these patients, transarterial chemoembolization (TACE) is the treatment of choice. However, the intermediate-stage comprises a heterogeneous subgroup of patients with considerable differences in tumor burden and liver function. In addition, differences in individual factors that are not captured by the BCLC framework, such as the tumor growth pattern, degree of hypervascularity, and vascular supply, com…

medicine.medical_specialtybusiness.industrypractical step-by-step guideReviewhepatocellular carcinomatransarterial chemoembolizationHypervascularityDiseasemedicine.disease03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisHepatocellular carcinomaMedicine030211 gastroenterology & hepatologyTumor growthLiver functiontreatment decision supportStage (cooking)businessLiver cancerIntensive care medicinesurvival predictionStaging systemJournal of Hepatocellular Carcinoma
researchProduct

Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference.

2009

The inhibition of the renin-angiotensin axis with the angiotensin II (ATII) receptor blockers, such as losartan, candesartan, and valsartan, has been demonstrated, similar to angiotensin-converting enzyme inhibitors, to reduce mortality in patients with arterial hypertension, chronic congestive heart failure, and acute myocardial infarction.1 Initially, the ATII receptor antagonist losartan helped to demonstrate new classes of ATII receptors and substantially expanded our knowledge about the cardiovascular effects of the renin-angiotensin-aldosterone system and its effector peptide ATII. Researchers dealing with this compound soon revealed that, beyond its antihypertensive effects attribute…

medicine.medical_specialtymedicine.drug_classMetabolitePharmacologyLosartanchemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansReceptorProtein Kinase CPhagocytesNADPH oxidasebiologyNADPH OxidasesReceptor antagonistAngiotensin IICandesartanEndocrinologyLosartanchemistryValsartanMatrix Metalloproteinase 9Hypertensionbiology.proteinAngiotensin II Type 1 Receptor Blockersmedicine.drugHypertension (Dallas, Tex. : 1979)
researchProduct

Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Cas…

2020

Abstract Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.

medicine.medical_specialtymedicine.medical_treatmentARNIlcsh:Medicineheart failureCase ReportheartCase Reports030204 cardiovascular system & hematologySacubitril03 medical and health sciences0302 clinical medicineInternal medicinemedicineEnalaprilVentricular remodelingReverse remodelingarrhythmic burdenremodelinglcsh:R5-920business.industrylcsh:RGeneral Medicinemedicine.diseaseImplantable cardioverter-defibrillatorfailureValsartan030220 oncology & carcinogenesisHeart failureCardiologylcsh:Medicine (General)businessSacubitril Valsartanmedicine.drugClinical Case Reports
researchProduct

The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fr…

2019

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 &plusmn

medicine.medical_specialtymedicine.medical_treatmentheart failureHemodynamics030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicinehemodynamicInternal medicinemedicineechocardiography030212 general & internal medicineEnalaprilremodelingEjection fractionbusiness.industryneprilysin inhibitionGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareValsartansacubitril/valsartanHeart failureCardiologyreduced ejection fractionDiureticbusinessNt-ProBNPSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct

L'enfant orphelin à la recherche de l'identité (Romain Gary, Jean-Paul Sartre)

2021

Childhood memories of R. Gary (Promise of the Morning) and J.-P. Sartre (Words) reflect a traumatic search for the identity of orphan boys. The modest image of the father contrasts in them with the mother’s vision of their future, containing everything that was missing in the lives of mothers. Writing as modus vivendi turned out to be an escape into the world of imagination, which, by protecting them from the real world, allowed them to understand this world.

memoriesGarySartreorphaned childidentity
researchProduct

<p>Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model</p>

2019

Background After a trauma, exuberant tissue healing with fibrosis of the joint capsule can lead to posttraumatic joint stiffness (PTJS). Losartan and atorvastatin have both shown their antifibrotic effects in different organ systems. Objective The purpose of this study was the evaluation of the influence of losartan and atorvastatin on the early development of joint contracture. In addition to joint angles, the change in myofibroblast numbers and the distribution of bone sialoprotein (BSP) were assessed. Study design and methods In this randomized and blinded experimental study with 24 rats, losartan and atorvastatin were compared to a placebo. After an initial joint injury, rat knees were …

musculoskeletal diseases0301 basic medicinePharmacologymedicine.medical_specialtyArticular capsule of the knee jointbusiness.industryAtorvastatinUrologyPharmaceutical SciencePlacebo03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureLosartan030220 oncology & carcinogenesisJoint stiffnessDrug DiscoveryJoint capsulemedicineJoint Contracturemedicine.symptomContracturebusinessmedicine.drugDrug Design, Development and Therapy
researchProduct

Lihavuus terveyden, sairauden ja normaaliuden määrittelyn kohteena

2018

Lihavuudesta ja lihavasta ruumiista on tullut viimeistään viime vuosikymmenen niin kutsutun lihavuusepidemiadiskurssin myötä keskeinen paitsi lääketieteellisen myös sosiaalisen ja moraalisen arvioinnin, yhteiskunnallisen keskustelun ja toimintaohjelmien kohde. Tässä katsausartikkelissa tarkastellaan ruumiin koon ja erityisesti lihavuuden määrittelyä. Artikkelissa eritellään ruumiin koon ja koon määrittelyn taustoja ja perusteita, ruumiin kokoon ja painoon liittyvää valtarakenteita, tiedontuotantoa, kulttuurisia ja sosiaalisia tekijöitä, ja niiden vaikutuksia. Artikkelissa lihavuuden normalisaatiopyrkimykset kytketään medikalisaatiokehitykseen, terveysaatteeseen ja uusliberaaliin eetokseen. …

obesitylcsh:GN1-890lcsh:History (General) and history of Europeneoliberalismlcsh:Anthropologyreview articlelcsh:GR1-950uusliberalismilcsh:History (General)health ideaslcsh:D1-2009katsausartikkelilcsh:Folkloremedikalisaatioterveysaatelcsh:DlihavuusmedicalizationJ@rgonia
researchProduct